# Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

Source: https://onco.cc/trials/nct04524689/  
OnCo record `nct04524689` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Tusamitamab ravtansine, Pembrolizumab, Cisplatin, Carboplatin and Pemetrexed in Non-small-cell lung cancer, run by Sanofi, recorded as terminated on the registry.

## Summary

Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC is a phase 2 interventional study registered as NCT04524689 by Sanofi, with 57 participants recorded, started 2020-10-26 and due to reach its primary completion in 2024-03-12. Interventions recorded: SAR408701 (Tusamitamab ravtansine), Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed. Conditions recorded: Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC).

Linked to the drug Tusamitamab ravtansine because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04524689
- Phase: 2
- Setting: Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Sponsor: Sanofi
- Enrolled: 57

## Sources

- ClinicalTrials.gov NCT04524689: https://clinicaltrials.gov/study/NCT04524689

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/), [Tusamitamab ravtansine](https://onco.cc/drugs/tusamitamab-ravtansine/)
- companies: [Sanofi](https://onco.cc/companies/sanofi/)

---
JSON: https://onco.cc/api/v1/entities/nct04524689.json